April 2008
BioWorld Today;4/14/2008, Vol. 19 Issue 72, p3
This section offers news briefs on the biotechnology industry. David J. Masso has resigned as president, CEO, and as a member of the board of directors of AEterna Zentaris Inc. Eugene Melnyk, former chairman and CEO of Biovail Corp., has withdrawn an application to the Ontario Supreme Court of Supreme, which accuses the company of improperly soliciting proxies for its 2008 annual meeting. The European Commission has given amrubicin hydrochloride from Celgene International Sarl an orphan drug designation.


Related Articles

  • Clinic Roundup.  // BioWorld Today;6/22/2012, Vol. 23 Issue 121, p9 

    The article offers news briefs on clinical trials in the biotechnology industry including the results of the Phase I trial of the oral PI3K/Akt inhibitor perifosine from Aeterna Zentaris Inc., the results of Phase III studies of the drug Northera from Chelsea Therapeutics, and the agreement...

  • Biotechnology in Canada.  // Biotechnology Industry Profile: Canada;November 2004, p1 

    Presents a profile of the Biotechnology industry in Canada. Executive summary of the industry; Market overview; Market value; Market segmentation; Competitive landscape; Leading companies in the industry; Market forecasts; Demographics; Further reading.

  • Stock Movers.  // BioWorld Today;5/7/2010, Vol. 21 Issue 88, p2 

    A list of biotechnology companies and the changes in their stocks is presented including NASDAQ Biotechnology, Aeterna Zentaris Inc. and Allos Therapeutics Inc.

  • WEEK IN REVIEW.  // BioWorld Insight;11/25/2013, Vol. 21 Issue 48, p5 

    The article offers information on various issues related to biotechnology industry as of November 2013 including the public offering from Aeterna Zentaris Inc., the agreement between Cell Therapeutics Inc. and Baxter International Inc., and the partnership between Eli Lilly and Co. and Qiagen NV.

  • Clinic Roundup.  // BioWorld Today;2/6/2012, Vol. 23 Issue 15, p4 

    This section offers news briefs on the biotechnology industry, including the results of the initial phase of Aeterna Zentaris Inc.'s ongoing trial of AEZS-108 in prostate cancer, the release of preliminary data from a drug interaction trial of cabozanitib in renal cell carcinoma by Exelixis Inc....

  • OTHERS NEWS TO NOTE.  // BioWorld Today;8/15/2007, Vol. 18 Issue 158, p5 

    This section offers news briefs on the biotechnology industry. AEterna Zentaris Inc. has promoted Jurgen Ernst to chairman of the board of directors. The field trials of Athenix Corp. showed corn plants featuring a new class of genes that can withstand at least eight times the standard field...

  • FINANCINGS ROUNDUP.  // BioWorld Today;6/22/2010, Vol. 21 Issue 119, p6 

    This section offers news briefs on financing deals within the biotechnology industry. Aeterna Zentaris Inc. has concluded its registered direct offering of 12.1 million U.S. dollar of units which include shares and common share purchase warrants. Aradigm Corp. has announced plans to raise 5...

  • Clinic Roundup.  // BioWorld Today;6/30/2010, Vol. 21 Issue 125, p8 

    This section offers world news briefs related to the biotechnology industry. Aeterna Zentaris in Quebec, Quebec, has received scientific advice regarding the Phase III trial for the development of its anticancer compound perifosine from the European Medicines Agency. A Phase III trial of...

  • OTHER NEWS TO NOTE.  // BioWorld Today;6/30/2008, Vol. 19 Issue 126, p2 

    This section offers news briefs related to biotechnology industries. AEterna Zentaris Inc. has completed the sale of a building in Quebec City, Quebec for $7.1 million in cash. Nanocopoeia has entered into an agreement Worldiscoveries to co-develop the biomedical uses of arborescent...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics